{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:00:36Z","timestamp":1783947636122,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["UL1TR001876"],"award-info":[{"award-number":["UL1TR001876"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["KL2TR001877"],"award-info":[{"award-number":["KL2TR001877"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008258","name":"hyundai hope on wheels","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]},{"name":"childrens national gala"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00520-022-06818-9","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T14:18:44Z","timestamp":1641910724000},"page":"3513-3520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population"],"prefix":"10.1007","volume":"30","author":[{"given":"Shana S.","family":"Jacobs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Dome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiang","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Postell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S.","family":"Hinds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"van den Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Mowbray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"6818_CR1","doi-asserted-by":"publisher","unstructured":"Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. Published online April 19, 2010. https:\/\/doi.org\/10.1200\/JCO.2009.27.0421","DOI":"10.1200\/JCO.2009.27.0421"},{"issue":"11","key":"6818_CR2","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1002\/cncr.11408","volume":"97","author":"JT Hickok","year":"2003","unstructured":"Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer 97(11):2880\u20132886. https:\/\/doi.org\/10.1002\/cncr.11408","journal-title":"Cancer"},{"issue":"3","key":"6818_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00280-005-1033-0","volume":"56","author":"R de Wit","year":"2005","unstructured":"de Wit R, Aapro M, Blower PR (2005) Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients? Cancer Chemother Pharmacol 56(3):231\u2013238. https:\/\/doi.org\/10.1007\/s00280-005-1033-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"6818_CR4","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.ejca.2011.04.014","volume":"47","author":"EA Laugsand","year":"2011","unstructured":"Laugsand EA, Fladvad T, Skorpen F et al (2011) Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids. Eur J Cancer 47(11):1682\u20131691. https:\/\/doi.org\/10.1016\/j.ejca.2011.04.014","journal-title":"Eur J Cancer"},{"issue":"6","key":"6818_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1185\/030079905X46313","volume":"21","author":"M Aapro","year":"2005","unstructured":"Aapro M (2005) Optimising antiemetic therapy: what are the problems and how can they be overcome? Curr Med Res Opin 21(6):885\u2013897. https:\/\/doi.org\/10.1185\/030079905X46313","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"6818_CR6","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1200\/JCO.2002.09.064","volume":"20","author":"R Kaiser","year":"2002","unstructured":"Kaiser R, Sezer O, Papies A et al (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20(12):2805\u20132811. https:\/\/doi.org\/10.1200\/JCO.2002.09.064","journal-title":"J Clin Oncol"},{"issue":"5","key":"6818_CR7","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/cpt.1322","volume":"105","author":"R Huddart","year":"2019","unstructured":"Huddart R, Fohner AE, Whirl-Carrillo M et al (2019) Standardized biogeographic grouping system for annotating populations in pharmacogenetic research. Clin Pharmacol Ther 105(5):1256\u20131262. https:\/\/doi.org\/10.1002\/cpt.1322","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"6818_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/cpt.598","volume":"102","author":"GC Bell","year":"2017","unstructured":"Bell GC, Caudle KE, Whirl-Carrillo M et al (2017) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther 102(2):213\u2013218. https:\/\/doi.org\/10.1002\/cpt.598","journal-title":"Clin Pharmacol Ther"},{"key":"6818_CR9","doi-asserted-by":"publisher","unstructured":"Aka I, Bernal CJ, Carroll R, Maxwell-Horn A, Oshikoya KA, VanDriest SL (2017) Clinical pharmacogenetics of cytochrome P450-associated drugs in children. J Pers Med Basel 7(4):14. http:\/\/dx.doi.org.proxygw.wrlc.org\/https:\/\/doi.org\/10.3390\/jpm7040014","DOI":"10.3390\/jpm7040014"},{"issue":"6","key":"6818_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.clpt.2005.08.015","volume":"78","author":"MO Babaoglu","year":"2005","unstructured":"Babaoglu MO, Bayar B, Aynacioglu AS et al (2005) Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther 78(6):619\u2013626. https:\/\/doi.org\/10.1016\/j.clpt.2005.08.015","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"6818_CR11","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.3109\/10428194.2014.898761","volume":"55","author":"H-R He","year":"2014","unstructured":"He H-R, Liu P, He G-H et al (2014) Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis. Leuk Lymphoma 55(12):2793\u20132800. https:\/\/doi.org\/10.3109\/10428194.2014.898761","journal-title":"Leuk Lymphoma"},{"key":"6818_CR12","doi-asserted-by":"crossref","unstructured":"Horinouchi M, Sakaeda T, Nakamura T, Morita Y, et al. (2002) Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: Functional relevance to pharmacokinetics of digoxin. Pharm Res N Y 19(10):1581\u20131585.","DOI":"10.1023\/A:1020433422259"},{"issue":"3","key":"6818_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/sj.tpj.6500413","volume":"7","author":"GD Leschziner","year":"2007","unstructured":"Leschziner GD, Andrew T, Pirmohamed M, Johnson MR (2007) ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 7(3):154\u2013179. https:\/\/doi.org\/10.1038\/sj.tpj.6500413","journal-title":"Pharmacogenomics J"},{"key":"6818_CR14","doi-asserted-by":"publisher","unstructured":"Brinkmann U (2002) Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo. Novartis Found Symp. 243:207\u2013210; discussion 210\u2013212, 231\u2013235. https:\/\/doi.org\/10.1002\/0470846356.ch15","DOI":"10.1002\/0470846356.ch15"},{"issue":"8","key":"6818_CR15","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.clinthera.2014.06.016","volume":"36","author":"H He","year":"2014","unstructured":"He H, Yin J-Y, Xu Y-J et al (2014) Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting. Clin Ther 36(8):1242-1252.e2. https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.016","journal-title":"Clin Ther"},{"issue":"10","key":"6818_CR16","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/j.1365-2044.2010.06476.x","volume":"65","author":"EM Choi","year":"2010","unstructured":"Choi EM, Lee MG, Lee SH, Choi KW, Choi SH (2010) Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting: association of ABCB1 polymorphisms with the efficacy of ondansetron. Anaesthesia 65(10):996\u20131000. https:\/\/doi.org\/10.1111\/j.1365-2044.2010.06476.x","journal-title":"Anaesthesia"},{"issue":"9","key":"6818_CR17","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s11605-018-3788-8","volume":"22","author":"P L\u00f3pez-Morales","year":"2018","unstructured":"L\u00f3pez-Morales P, Flores-Funes D, S\u00e1nchez-Migall\u00f3n EG, Lir\u00f3n-Ruiz RJ, Aguayo-Albasini JL (2018) Genetic factors associated with postoperative nausea and vomiting: a systematic review. J Gastrointest Surg 22(9):1645\u20131651. https:\/\/doi.org\/10.1007\/s11605-018-3788-8","journal-title":"J Gastrointest Surg"},{"issue":"11","key":"6818_CR18","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1200\/JCO.2003.05.164","volume":"21","author":"P-B Tremblay","year":"2003","unstructured":"Tremblay P-B, Kaiser R, Sezer O et al (2003) Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 21(11):2147\u20132155. https:\/\/doi.org\/10.1200\/JCO.2003.05.164","journal-title":"J Clin Oncol"},{"key":"6818_CR19","doi-asserted-by":"publisher","unstructured":"Niesler B (2008) Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics Lond 9(5):501\u2013504. http:\/\/dx.doi.org.proxygw.wrlc.org\/https:\/\/doi.org\/10.2217\/14622416.9.5.501","DOI":"10.2217\/14622416.9.5.501"},{"issue":"5","key":"6818_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00008571-200405000-00001","volume":"14","author":"R Kaiser","year":"2004","unstructured":"Kaiser R, Sezer O, Possinger K, Roots I, Brockmoller J (2004) Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics 14(5):271\u2013278","journal-title":"Pharmacogenetics"},{"issue":"7","key":"6818_CR21","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/pbc.24463","volume":"60","author":"BB Reeve","year":"2013","unstructured":"Reeve BB, Withycombe JS, Baker JN et al (2013) The first step to integrating the child\u2019s voice in adverse event reporting in oncology trials: a content validation study among pediatric oncology clinicians. Pediatr Blood Cancer 60(7):1231\u20131236. https:\/\/doi.org\/10.1002\/pbc.24463","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"6818_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26261","volume":"64","author":"BB Reeve","year":"2017","unstructured":"Reeve BB, McFatrich M, Pinheiro LC et al (2017) Eliciting the child\u2019s voice in adverse event reporting in oncology trials: cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative. Pediatr Blood Cancer 64(3):e26261. https:\/\/doi.org\/10.1002\/pbc.26261","journal-title":"Pediatr Blood Cancer"},{"key":"6818_CR23","unstructured":"xTAG CYP2D6 kit v3. Luminex. Published 2020 2006. Accessed October 18, 2020. https:\/\/www.luminexcorp.com\/cyp2d6\/)"},{"issue":"7","key":"6818_CR24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/FPC.0b013e32832e0e97","volume":"19","author":"RP Owen","year":"2009","unstructured":"Owen RP, Sangkuhl K, Klein TE, Altman RB (2009) Cytochrome P450 2D6. Pharmacogenet Genomics 19(7):559\u2013562. https:\/\/doi.org\/10.1097\/FPC.0b013e32832e0e97","journal-title":"Pharmacogenet Genomics"},{"key":"6818_CR25","unstructured":"R: A language and environment for statistical computing. The R Project for Statistical computing. Accessed October 14, 2020. https:\/\/www.r-project.org"},{"issue":"2","key":"6818_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/cpt.598","volume":"102","author":"GC Bell","year":"2017","unstructured":"Bell GC, Caudle KE, Whirl-Carrillo M et al (2017) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther 102(2):213\u2013218. https:\/\/doi.org\/10.1002\/cpt.598","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"6818_CR27","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.17219\/acem\/69451","volume":"27","author":"P Niewi\u0144ski","year":"2018","unstructured":"Niewi\u0144ski P, Wojciechowski R, \u015aliwi\u0144ski M et al (2018) CYP2D6 basic genotyping as a potential tool to improve antiemetic efficacy of ondansetron in prophylaxis of postoperative nausea and vomiting. Adv Clin Exp Med 27(11):1499\u20131503. https:\/\/doi.org\/10.17219\/acem\/69451","journal-title":"Adv Clin Exp Med"},{"issue":"10","key":"6818_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11912-019-0840-0","volume":"21","author":"F Sherani","year":"2019","unstructured":"Sherani F, Boston C, Mba N (2019) Latest update on prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients. Curr Oncol Rep 21(10):89. https:\/\/doi.org\/10.1007\/s11912-019-0840-0","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"6818_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/mpo.2950160408","volume":"16","author":"S LeBaron","year":"1988","unstructured":"LeBaron S, Zeltzer LK, LeBaron C, Scott SE, Zeltzer PM (1988) Chemotherapy side effects in pediatric oncology patients: drugs, age, and sex as risk factors. Med Pediatr Oncol 16(4):263\u2013268. https:\/\/doi.org\/10.1002\/mpo.2950160408","journal-title":"Med Pediatr Oncol"},{"issue":"4","key":"6818_CR30","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/cncr.21631","volume":"106","author":"MT Holdsworth","year":"2006","unstructured":"Holdsworth MT, Raisch DW, Frost J (2006) Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 106(4):931\u2013940. https:\/\/doi.org\/10.1002\/cncr.21631","journal-title":"Cancer"},{"issue":"10","key":"6818_CR31","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/pbc.25108","volume":"61","author":"JL Freedman","year":"2014","unstructured":"Freedman JL, Faerber J, Kang TI et al (2014) Predictors of antiemetic alteration in pediatric acute myeloid leukemia. Pediatr Blood Cancer 61(10):1798\u20131805. https:\/\/doi.org\/10.1002\/pbc.25108","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"6818_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27584","volume":"66","author":"LL Dupuis","year":"2019","unstructured":"Dupuis LL, Tamura RN, Kelly KM et al (2019) Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy. Pediatr Blood Cancer 66(4):e27584. https:\/\/doi.org\/10.1002\/pbc.27584","journal-title":"Pediatr Blood Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06818-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-06818-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06818-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T16:16:42Z","timestamp":1645201002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-06818-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["6818"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-06818-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-762220\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"4 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board at Children\u2019s National Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Parents (for children less than 18) or participants provided informed consent according to institutional guidelines. Patients 7 to 17 also provided assent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}